Coronary Artery Bypass Grafting, Coronary Artery Disease, Heart Diseases
Conditions
Brief summary
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grafting (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grafting (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,300 women randomized 1:1 to MAG or SAG. Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.
Detailed description
ROMA:Women will leverage the infrastructure and the existing women population of the ROMA trial. ROMA:Women has two key Aims. In Aim 1, the investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,300 women randomized 1:1 to MAG or SAG. In Aim 2, the investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG. Differences by important subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. ROMA:Women is a two-arm, international, multi-center, randomized clinical trial nested in the ROMA trial. ROMA:Women will include all the women enrolled in the parent ROMA trial and will leverage the existing ROMA infrastructure including clinical trial unit, database, case report forms (CRF), randomization system, site training resources, informed consent forms (ICF), regulatory approvals, Central Events Review Committee (CEC) processes/personnel, network of participating sites, site PIs, and study coordinators. The planned randomization procedure, interventions and treatment arms, outcome assessments and follow-up protocol of ROMA:Women are identical to those of the currently ongoing parent ROMA trial. The sites participating in ROMA will continue enrollment of women after the completion of the ROMA trial and additional sites will also be opened to reach the target sample size of ROMA:Women.
Interventions
PROCEDURESingle arterial graft
This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
PROCEDUREMultiple arterial grafting
This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
Sponsors
Weill Medical College of Cornell University
New York Presbyterian Hospital
Sunnybrook Health Sciences Centre
Cedars-Sinai Medical Center
Columbia University
Duke University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
The endpoint assessors will be blinded to treatment allocation (PROBE).
Intervention model description
Patients undergoing coronary artery bypass surgery will be in one of two groups. One group will receive a single arterial graft and the second group will receive two or more arterial grafts.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Women patients ≥18 years old. 2. Isolated coronary artery bypass grafting. 3. Primary (first time) cardiac surgery procedure. 4. Significant disease of the left main coronary artery or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.
Exclusion criteria
* Male gender * Single graft * Emergency operation * Myocardial infarction within 72 hours of surgery * Left ventricular ejection fraction \< 35% * Any concomitant cardiac or non-cardiac procedure * Previous cardiac surgery * Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduces life expectancy to less than 5 years. * Inability to use the saphenous vein or to use both radial and right internal thoracic arteries * Anticipated need for coronary thrombo-endarterectomy * Planned hybrid revascularization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary outcome for aim 1: Death from any cause, any stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure. | Postoperatively, minimum 2.5 year follow-up | The primary outcome for aim 1 will be a composite of the first occurrence of death from any cause, any stroke, non-procedural myocardial infarction (\>48 hours after surgery), repeat revascularization and hospital readmission for acute coronary syndrome or heart failure. |
| Primary outcome for aim 2: Disease-specific quality of life | Postoperatively, minimum 2.5 year follow-up | Assessed using the Seattle Angina Questionnaire (SAQ), a validated 19-item questionnaire that measures five domains related to coronary disease: angina frequency, physical limitations, quality of life, angina stability, and treatment satisfaction. Scores range from 0 to 100 with higher scores indicating fewer symptoms and better health status. The minimum clinically important difference on the SAQ is 5 points. The primary endpoint for aim 2 is the absolute change in the Seattle Angina Questionnaire (SAQ) at 12 months compared to baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Death from any cause, any stroke, non-procedural myocardial infarction, and repeat revascularization. | Postoperatively, minimum 2.5 year follow-up | One of the secondary outcomes for aim 1: It will be a composite of the first occurrence of death from any cause, any stroke, non-procedural myocardial infarction (\>48 hours after surgery), and repeat revascularization. This is the primary outcome of the parent ROMA trial. |
| Death from cardiac cause, any stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure. | Postoperatively, minimum 2.5 year follow-up | Another secondary outcome for aim 1: It will be a composite of the first occurrence of death from cardiac cause, any stroke, non-procedural myocardial infarction (\>48 hours after surgery), repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure. |
| Death from any cause | Postoperatively, minimum 2.5 year follow-up | Another secondary outcome for aim 1: Death will be considered to be cardiac unless a definite non-cardiac cause is identified. |
| Stroke | Postoperatively, minimum 2.5 year follow-up | Another secondary outcome for aim 1: Based on the American Heart Association/American Stroke Association Expert Consensus stroke definition, stroke will be identified in case of: 1. pathological, imaging, or other objective evidence of cerebral ischemic injury in a defined vascular distribution; OR 2. clinical evidence of cerebral ischemic injury based on symptoms persisting ≥24 hours or until death, and other etiologies excluded. |
| Non-procedural myocardial infarction | > 48 hours postoperatively, minimum 2.5 year follow-up | Another secondary outcome for aim 1: Based on the 4th Universal Definition, non-periprocedural myocardial infarction will be identified in case of detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia with at least one of the following: 1. symptoms of ischemia 2. electrocardiogram changes indicative of new ischemia (new ST-T changes or new left bundle branch block) 3. development of pathological Q waves in the electrocardiogram 4. imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. |
| Repeat revascularization | Postoperatively, minimum 2.5 year follow-up | Another secondary outcome for aim 1: Repeat revascularization will include any percutaneous or surgical revascularization on a grafted coronary artery after the initial operation. |
| Readmission for acute coronary syndrome | Postoperatively, minimum 2.5 year follow-up | Another secondary outcome for aim 1: Prolonged ischemic symptoms at rest (usually ≥10 minutes in duration), or accelerating pattern of chest pain that occurs with a lower activity threshold (CCS class III or IV) considered to be myocardial ischemia upon final diagnosis resulting in an unscheduled visit to a healthcare facility resulting in an overnight stay generally within 24 hours of the most recent symptoms, cardiac biomarkers not meeting MI criteria, and ECG or angiographic evidence of ischemia. |
| Readmission for heart failure | Postoperatively, minimum 2.5 year follow-up | Another secondary outcome for aim 1: While patients may have multiple simultaneous disease processes, for the outcome event of heart failure requiring hospitalization, the diagnosis of congestive heart failure would need to be the primary process. Heart failure (HF) requiring hospitalization is defined as an event that meets the following criteria: i. Requires hospitalization AND ii. Clinical symptoms of heart failure AND iii. Physical signs of heart failure AND iv. Need for additional/increased therapy AND v. No other non-cardiac etiology (such as chronic obstructive pulmonary disease, hepatic cirrhosis, acute renal failure, or venous insufficiency) and no other cardiac etiology (such as pulmonary embolus, cor pulmonale, primary pulmonary hypertension, or congenital heart disease) for signs or symptoms are identified. |
| Generic quality of life according to the Short Form Health Survey (SF-12v2) | Postoperatively, minimum 2.5 year follow-up | Secondary outcomes for aim 2: The SF-12v12 measures eight dimensions of health: physical functioning, role limitations due to physical problems, bodily pain, vitality, general health perception, social function, role limitations due to emotional problems, and mental health. Scores for each domain range from 0 to 100 with higher scores indicating better health status. The SF-12v2 has two summary measures: physical and mental self-perceived health with norm-based methods that standardize the score to a mean of 50 and standard deviation of 10. |
| Generic quality of life according to EuroQuol-5D (EQ-5D) | Postoperatively, minimum 2.5 year follow-up | Secondary outcomes for aim 2: EQ-5D is a five-item instrument to assess health status in the following five dimensions: mobility, self-care, usual activity, pain or discomfort, and anxiety or depression. Individual domain scores will be converted to a summary index representing utility weights, which allow conduct of cost-effectiveness analyses. |
| Mental and physical health symptoms according to PROMIS instruments | Postoperatively, minimum 2.5 year follow-up | Secondary outcomes for aim 2: Physical and mental health symptoms and physical functioning will be measured with standardized PROMIS instruments, including: Pain interference, Neuropathic Pain, Fatigue, Sleep disturbance, Depression, Anxiety, and Physical Function. A mean of 50 and a standard deviation of 10 represent the general population in the US. |
Countries
Australia, Austria, Brazil, Canada, China, Croatia, Czechia, Denmark, Germany, India, Israel, Italy, Japan, Netherlands, North Macedonia, Poland, Portugal, Russia, Serbia, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Contacts
CONTACTMario Gaudino, Prof/PhD/MD
CONTACTStephen Fremes, Prof/MD
PRINCIPAL_INVESTIGATORMario Gaudino, Prof/PhD/MD
Weill Medical College of Cornell University
PRINCIPAL_INVESTIGATORStephen Fremes, MD
Sunnybrook Health Sciences Centre
PRINCIPAL_INVESTIGATORRuth Masterson Creber, RN, PhD
Columbia University
PRINCIPAL_INVESTIGATORC. Noel Bairey Merz, MD
Cedars-Sinai
PRINCIPAL_INVESTIGATORKarla Ballman, PhD
Weill Medical College of Cornell University
PRINCIPAL_INVESTIGATORSean O'Brien, PhD
Duke University
Outcome results
None listed